PRO: Prothrombin Complex Concentrate Should Be Used in Preference to Fresh Frozen Plasma for Hemostasis in Cardiac Surgical Patients

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 32, Issue 2, 2018, Pages 1062-1067

  Bhatt, Himani V ^a   Subramaniam, Kathirvel ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

bleeding; cardiac surgery; fresh frozen plasma; hemostasis; prothrombin complex concentrate

Indexed keywords

ANTIVITAMIN K; FRESH FROZEN PLASMA; PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR;

CARDIOPULMONARY BYPASS; CLINICAL TRIAL; HEART SURGERY; HEART TRANSPLANTATION; HEMOSTASIS; HUMAN; NOTE; PEDIATRIC SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL PATIENT; THROMBOEMBOLISM; HEMOSTATIC TECHNIQUE; PLASMA;

BLOOD COAGULATION FACTORS; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HEMOSTASIS; HEMOSTATIC TECHNIQUES; HUMANS; PLASMA;

EID: 85040343316     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2017.05.044     Document Type: Note

References (41)

1. Sorensen, B., Spahn, D.R., Innerhofer, P., et al. Clinical review: Prothrombin complex concentrates–Evaluation of safety and thrombogenicity. Critical Care, 15, 2011, 201.
2. Keeling, D., Baglin, T., Campbell, T., et al. Guidelines on oral anticoagulation with warfarin–Fourth edition. Br J Haematol 154 (2011), 311–324.
3. Tran, H.A., Chunilal, S.D., Harper, P.L., et al. An update on consensus guidelines for warfarin reversal. Med J Aus 198 (2013), 198–199.
4. van der Meer, F.J., Rosendaal, F.R., Vandenbroucke, J.P., et al. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153 (1993), 1557–1562.
5. Beyth, R.J., Quinn, L.M., Landefeld, C.S., Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105 (1998), 91–99.
6. Bhatt, H.V., Fischer, G.W., Atrial fibrillation: Pathophysiology and therapeutic options. J Cardiothorac Vasc Anesth 29 (2015), 1333–1340.
7. Guyatt, G.H., Alk, E.A., Crowther, M., et al. Executive summary: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141 (2012), 7S–47S.
8. Leissinger, C.A., Blatt, P.M., Hoots, W.K., et al. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: A review of the literature. Am J Hematol 83 (2008), 137–143.
9. Jones, G.M., Erdman, M.J., Smetana, K.S., et al. 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal in severe bleeding: A multicenter, retrospective, propensity-matched pilot study. J Thromb Thrombolysis 42 (2016), 19–26.
10. Voils, S.A., Baird, B., Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: Does it matter?. Thromb Res 130 (2012), 833–840.
11. Sarode, R., Milling, T.J. Jr, Refaai, M.A., et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: A randomized, plasma-controlled, phase IIIb study. Circulation 128 (2013), 1234–1243.
12. Goldstein, J.N., Refaai, M.A., Milling, T.J. Jr, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: A phase 3b, open-label, non-inferiority, randomised trial. Lancet 385 (2015), 2077–2087.
13. Demeyere, R., Gillardin, S., Arnout, J., et al. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: A randomized study. Vox Sang 99 (2010), 251–260.
14. Wong, J.K., Chen, P.C., Falvey, J., et al. Anticoagulation reversal strategies for left ventricular assist device patients with acute intracranial hemorrhage. ASAIO J 62 (2016), 552–557.
15. Felli, A., Zeidler, P., Jilma, B., et al. Different heparin contents in prothrombin complex concentrates may impair blood clotting in outpatients with ventricular assist devices receiving phenprocoumon. J Cardiothorac Vasc Anesth 30 (2016), 96–101.
16. Nuckles, K.B., Pratt, J.H., Cameron, C.M., et al. Case series of four-factor prothrombin complex concentrate for warfarin reversal before heart transplantation. Transplant Proc 47 (2015), 841–843.
17. Kantorovich, A., Fink, J.M., Militello, M.A., et al. Low-dose 3-factor prothrombin complex concentrate for warfarin reversal prior to heart transplant. Ann Pharmacother 49 (2015), 876–882.
18. Mathia, T., Puca, K.E., Downey, F., et al. Use of vitamin K and prothrombin complex concentrate as warfarin reversal prior to heart transplant. J Heart Lung Transplant, 31, 2012, S154.
19. Wu, D.W., Joan, U., Szymanski, J., et al. Impact of four-factor prothrombin complex concentrate on urgent warfarin-reversal in patients with ventricular assist devices going for heart transplants. Blood, 126, 2015, 3568.
20. Cosgrove, R.H., Patanwala, A.E., Sears, B.L., et al. The use of three factor prothrombin complex concentrate to reverse warfarin treated mechanical circulatory device patients immediately prior to heart transplant. J Heart Lung Transplant 34:Suppl (2015), S54–S55.
21. Lee, J.K., Ing, C., Prothrombin complex concentrate and methylene blue for treatment of coagulopathy and vasoplegia in a pediatric heart transplant patient. AA Case Rep 6 (2016), 127–129.
22. Navaratnam, M., Ng, A., Williams, G.D., et al. Perioperative management of pediatric en-bloc combined heart-liver transplants: A case series review. Pediatr Anesth 26 (2016), 976–986.
23. Rybka, M.M., Samsonova, N.N., Klimovich, L.G., et al. Correction of hemostasis with blood products in the surgical treatment of congenital heart disease in infants and young children. Anesteziol Reanimatol 60 (2015), 42–46.
24. Hofer, J., Fries, D., Solomon, C., et al. A snapshot of coagulopathy after cardiopulmonary bypass. Clin Applied Thrombosis/Hemostasis 22 (2016), 505–511.
25. Cappabianca, G., Mariscalco, G., Biancari, F., et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care, 20, 2016, 5.
26. Song, H.K., Tibayan, F.A., Kahl, E.A., et al. Safety and efficacy of prothrombin complex concentrates for the treatment of coagulopathy after cardiac surgery. J Thorac Cardiovasc Surg 147 (2014), 1036–1040.
27. Ortmann, E., Besser, M.W., Sharples, L.D., et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 121 (2015), 26–33.
28. Arnékian, V., Camous, J., Fattal, S., et al. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact Cardiovasc Thorac Surg 15 (2012), 382–389.
29. Tanaka, K.A., Mazzeffi, M.A., Strauss, E.R., et al. Computational simulation and comparison of prothrombin complex concentrate dosing schemes for warfarin reversal in cardiac surgery. J Anesth 30 (2016), 369–376.
30. Magee, G., Peters, C., Zbrozek, A., Analysis of inpatient use of fresh frozen plasma and other therapies and associated outcomes in patients with major bleeds from vitamin K antagonism. Clin Ther 35 (2013), 1432–1443.
31. Refaai, M.A., Goldstein, J.N., Lee, M.L., et al. Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. Transfusion 55 (2015), 2722–2729.
32. Trevisan, D., Zavatti, L., Gabbieri, D., et al. Point-of-care-based protocol with first-line therapy with coagulation factor concentrates is associated with decrease allogenic blood transfusion and costs in cardiovascular surgery: An Italian single-center experience. Minerva Anestesiol 82 (2016), 1077–1088.
33. Hickey, M., Gatien, M., Taljaard, M., et al. Outcomes of urgent warfarin reversal with frozen plasma versus prothrombin complex concentrate in the emergency department. Circulation 128 (2013), 360–364.
34. Milling, T.J. Jr, Refaai, M.A., Sarode, R., et al. Safety of a four-factor prothrombin complex concentrate versus plasma for vitamin K antagonist reversal: An integrated analysis of two phase IIIb clinical trials. Acad Emerg Med 23 (2016), 466–475.
35. Dentali, F., Marchesi, C., Giorgi Pierfranceschi, M., et al. Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thromb Haemost 106 (2011), 429–438.
36. Bradford, C.D., Stahovich, M.J., Dembitsky, W.P., et al. Safety of prothrombin complex concentrate to control excess bleeding during continuous flow LVAD insertion. ASAIO J 61 (2015), 509–513.
37. Jablow, L.M., Jones, C.W., Carroll, G.G., et al. Limb-threatening deep venous thrombosis complicating warfarin reversal with three-factor prothrombin complex concentrate: A case report. J Emerg Med 50 (2016), 28–31.
38. Majeed, A., Eelde, A., Agren, A., et al. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res 129 (2012), 146–151.
39. Zemrak, W.R., Kelley, E., Kovacic, N.L., et al. Thrombotic complications following the administration of high-dose prothrombin complex concentrate for acute warfarin reversal. Am J Emerg Med, 34, 2015, 1736 e1–e3.
40. Wiedermann, C.J., A word of caution on renal risks of prothrombin complex concentrate use in cardiac surgery. Crit Care, 20, 2016, 63.
41. Wong, P.J., Bailey, A.M., Baum, R.A., Four-factor prothrombin complex concentrate-associated hypotension. Am J Emerg Med, 34, 2016, 2059 e1–e2.